Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04366830
NCT04366830No Longer AvailableNot Applicable

Intermediate-size Expanded Access of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome Due to COVID-19 Infection

Mesoblast International Sàrl1 site in 1 countryStarted: April 29, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
No Longer Available
Locations
1
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).

Detailed Description

This intermediate-size expanded access protocol plans to treat approximately 50 adult participants, male and female, with moderate to severe ARDS due to COVID-19 infection. Participants who are 18 years of age or older will be enrolled at multiple clinical sites across the United States.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •18 years or older
  • •Participant has coronavirus disease COVID-19 confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay or another diagnostic test
  • •Moderate to severe ARDS as determined by the following criteria (adapted from the Berlin criteria):
  • •Bilateral opacities must be present on a chest radiograph or computed tomographic (CT) scan. These opacities are not fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules.
  • •Respiratory failure not fully explained by cardiac failure or fluid overload. An objective assessment (e.g., echocardiography) to exclude hydrostatic pulmonary edema is required if no risk factors for ARDS are present.
  • •Moderate to severe impairment of oxygenation must be present, as defined by the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2). The severity of the hypoxemia defines the severity of the ARDS:
  • •Moderate ARDS: e PaO2/FiO2 >100 millimeters of mercury (mmHg) and ≤200 mmHg, on ventilator settings that include positive end-expiratory pressure (PEEP) ≥5 centimeters (cm) of water OR
  • •Severe ARDS: PaO2/FiO2 ≤100 mmHg on ventilator settings that include PEEP ≥5 cm of water
  • •≤72 hours post-initiation of ventilation
  • •High sensitivity C-reactive protein (hs-CRP) serum level ≥ 4.0 milligrams per deciliter (mg/dL)
  • •Acute Physiologic and Chronic Health Evaluation (APACHE II) score ≥5
  • •Aspartate aminotransferase/alanine transaminase (AST/ALT) < 5x upper limit of normal (ULN)
  • •Creatinine clearance ≥ 30 milliliters per minute (mL/min)
  • •Serum creatinine <2 mg/dL

Exclusion Criteria

  • •Participant is receiving extracorporeal membrane oxygenation (ECMO)
  • •Females who are pregnant or lactating
  • •Known hypersensitivity to dimethyl sulfoxide (DMSO) or to porcine or bovine proteins
  • •Severe chronic obstructive pulmonary disease (COPD) requiring oxygen therapy prior to becoming ill with ARDS due to COVID-19 infection
  • •Any end-stage organ disease which, in the opinion of the treating physician, may possibly affect the safety of the remestemcel-L treatment

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
NCT04456439Mesoblast International Sàrl
Unknown
Not Applicable
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 SyndromePost COVID-19 Syndrome
NCT04798066Hope Biosciences Research Foundation
Approved For Marketing
Not Applicable
An Intermediate Size Expanded Access Protocol of AMX0035 for ALSAmyotrophic Lateral Sclerosis
NCT05286372Amylyx Pharmaceuticals Inc.
No Longer Available
Not Applicable
A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSDPost Traumatic Stress Disorder
NCT04438512Lykos Therapeutics
Available
Not Applicable
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)Spinocerebellar AtaxiasSCA
NCT06034886Biohaven Pharmaceuticals, Inc.
Intermediate-size Expanded Access Program... | Clinical Trial